Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma.

ABSTRACT: Standard pomalidomide dosing (4 mg/day for 21 of 28 days) achieved the most robust pharmacokinetic (PK) and pharmacodynamic (PD) effects. Daily dosing with pomalidomide 2 mg is a safe alternative for patients at risk of toxicity; alternate-day dosing was less effective.

SUBMITTER: Seefat MR 

PROVIDER: S-EPMC12819103 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature